AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn s disease and ulcerative colitis reinforcing AbbVie s commitment to advancing.
Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of fruquintinib a selective inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer mCRC.